
15-12B
1
d742028d1512b.htm
15-12B

15-12B

 
  UNITED STATES 
SECURITIES AND EXCHANGE COMMISSION 
Washington, D.C. 20549   
  FORM 15
    
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION 
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) 
OF THE SECURITIES EXCHANGE ACT OF 1934. 
Commission File Number 001-33415 
   
Orexigen Therapeutics, Inc. 
(Exact name of registrant as specified in its charter)   
  3344 N.
Torrey Pines Ct., Suite 200  La Jolla, CA 92037 
(858) 875-8600 
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices) 
Common Stock, par value $0.001 per share 
(Title of each class of securities covered by this Form) 
None  (Titles of all
other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)   
  Please place an
X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:   








Rule 12g-4(a)(1)
 

 
 ☒

Rule 12g-4(a)(2)
 

 
 ☐

Rule 12h-3(b)(1)(i)
 

 
 ☒

Rule 12h-3(b)(1)(ii)
 

 
 ☐

Rule 15d-6
 

 
 ☐

Rule 15d-22(b)
 

 
 ☐
 Approximate number of holders of record as of the certification or notice date: 0 
Pursuant to the requirements of the Securities Exchange Act of 1934 Orexigen Therapeutics, Inc. has caused this certification/notice to be
signed on its behalf by the undersigned duly authorized person.   










Date: 
 
May 31, 2019
    
 Orexigen Therapeutics, Inc.







 

    
By: 
 
 /s/ Thomas P. Lynch


 

    
 Name:
 
 Thomas P. Lynch


 

    
 Title:
 
 Chief Administrative Officer, General Counsel, President, Secretary and Treasurer
    
 



